Also trades as RMD.AX.
RMD
Premium GrowerAI pickResMed Inc. · Healthcare · United States · $35.6B cap · $315.9M/day traded
$238.53 +1.9% · close 11 Nov · scored 12 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
Around its 29 Oct results, analysts left next year's EPS estimate little changed.
As of 12 Nov 2026, the MoatMap Score for ResMed Inc. (RMD) is 88/100, ranked against 25,000+ stocks in 38 markets (Quality 85, Value 44, Momentum 61, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ResMed is the global leader in CPAP devices and masks for sleep apnea, a condition that remains heavily underdiagnosed worldwide. It has a large installed base of connected devices that generates recurring, high-margin mask and accessory resupply revenue. The company earns high returns on capital, funds growth and a buyback from its own cash flow, and has no need to refinance. That matters in a world where yields stay high and punish long-duration, levered growth. Much of the de-rating came from fear that GLP-1 weight-loss drugs would shrink the patient pool. Evidence so far suggests those patients are entering care and staying on therapy, and analysts have recently upgraded the stock. On a moderate valuation for its quality, owner earnings can compound without heroic assumptions. Insider selling in the last 90 days was negligible (0.02% of shares).
ABOUT RESMED INC.
Read
ResMed Inc. is a global leader in medical devices and cloud-based software solutions for treating and managing sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its competitive moat is its innovative product portfolio, extensive patent protection, global distribution network, and leadership in connected health solutions that enhance patient adherence and outcomes. ResMed is a dominant player in sleep and respiratory care, benefiting from a growing addressable market and strong R&D.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 3.6B | 4.2B | 4.7B | 5.1B | 12.9% | 5.7B | 5.3B | 5.6B | 3.2% |
| EPS | 3.27 | 5.34 | 6.12 | 6.94 | 9.57 | 30.8% | 10.98 | 10.40 | 11.33 | 5.8% |
| Shares | — | 146.4M | 147.1M | 146.9M | 146.4M | -0.0% | 140.7M | — | — | — |
| Debt | — | 917.5M | 1.6B | 873.9M | 851.8M | -2.4% | 610.6M | — | — | — |
| Equity | — | 3.4B | 4.1B | 4.9B | 6.0B | 21.1% | — | — | — | — |
| Op CF | — | 351.1M | 693.3M | 1.4B | 1.8B | 70.9% | 1.8B | — | — | — |
| Inv CF | — | -229.9M | -1.2B | -269.8M | -200.0M | — | — | — | — | — |
| Fin CF | — | -128.4M | 422.9M | -1.1B | -606.3M | — | — | — | — | — |
Above its 200-day average and 13% below its 52-week high.
Calmer than 72% of stocks we rank over the past year (volatility 31% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RMD are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| RMD | ResMed Inc.(you) | $35.6B | 88 |
| BDX | Becton, Dickinson and Company | $54.2B | 87 |
| WST | West Pharmaceutical Services, Inc. | $27.6B | 81 |
| ALGN | Align Technology, Inc. | $11.0B | 88 |
| BAX | Baxter International Inc. | $13.1B | 74 |
| AVTR | Avantor, Inc. | $11.7B | 74 |
| MMSI | Merit Medical Systems, Inc. | $5.6B | 88 |
| SOLV | Solventum Corporation | $14.5B | 66 |
| COO | The Cooper Companies, Inc. | $11.6B | 68 |
| NVST | Envista Holdings Corporation | $3.8B | 88 |
Peer medians: ROE -31.5% · P/E 26.7x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.